Multiple Myeloma Clinical Trial
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
Summary
This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.
Full Description
PRIMARY OBJECTIVE:
I. Compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) used as initial therapy for patients with newly diagnosed MM.
OUTLINE: This is an observational study.
Patients have their medical records reviewed on study.
Eligibility Criteria
Inclusion Criteria:
Previously untreated active multiple myeloma starting a new treatment for the disease with one of the three established treatment regimens: VRd (bortezomib, lenalidomide, dexamethasone), DRd (daratumumab lenalidomide dexamethasone), or DVRd (daratumumab, bortezomib, lenalidomide, and dexamethasone)
No prior treatment for myeloma
Not receiving concurrent treatment for another active malignancy
No more than 3 months from start of treatment
Exclusion Criteria:
Does not meet all inclusion criteria
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Scottsdale Arizona, 85259, United States More Info
Principal Investigator
Jacksonville Florida, 32224, United States More Info
Principal Investigator
Rochester Minnesota, 55905, United States More Info
Principal Investigator
La Crosse Wisconsin, 54601, United States More Info
Principal Investigator
How clear is this clinincal trial information?